Diligence memo · auto-generated · as of July 2, 2026
NextCure, Inc.
NextCure, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
NextCure, Inc. operates in Biotechnology, based in BELTSVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NextCure, Inc. has raised $130M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $93M on 2018-11-05.
Most recent recorded round closed around 2025-11-12.
Valuation (modeled)modeled
Provath models NextCure, Inc. at approximately $114M (range $67M–$143M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.59× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 59 months.
Last raise 8 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 4.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 93% of Biotechnology peers (4293 compared).
Modeled value ranks above 61% of those peers.
Closest niche peers: Newleos Therapeutics, Inc., Biolinq Inc, Atsena Therapeutics, Inc., Galvanize Therapeutics, Inc., X4 Pharmaceuticals, Inc.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.